Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab-based treatment combinations for advanced clear cell renal cell carcinoma
NL-OMON59857Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and quavonlimab in renal cell carcinoma (RCC), sponsored by Merck & Co. Primary endpoints: Number of participants with one or more dose-limiting toxicities in the safety lead-in phase, Number of participants with one or more adverse events in the safety lead-in phase and 5 more. Started Jun 2023; status: completed.
02
Drugs
pembrolizumabquavonlimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON59857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59857.